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Intensity of Statin Therapy
in Relation to Myocardial Ischemia,
Troponin T Release, and Clinical Cardiac Outcome
in Patients Undergoing Major Vascular Surgery
Harm H. H. Feringa, MD,* Olaf Schouten, MD,† Stefanos E. Karagiannis, MD,* Jasper Brugts, MD,*
Abdou Elhendy, MD,§ Eric Boersma, PHD,* Radosav Vidakovic, MD,*
Marc R. H. M. van Sambeek, MD,† Peter G. Noordzij, MD,‡ Jeroen J. Bax, MD,¶
Don Poldermans, MD‡
Rotterdam and Leiden, the Netherlands; and Marshfield, Wisconsin
Objectives This study sought to examine whether higher statin doses and lower low-density lipoprotein (LDL) cholesterol are
associated with improved cardiac outcome in vascular surgery patients.
Background Statins may have cardioprotective effects during major vascular surgery.
Methods In a prospective study of 359 vascular surgery patients, statin dose and cholesterol levels were recorded preop-
eratively. Myocardial ischemia and heart rate variability were assessed by 72-h 12-lead electrocardiography
starting 1 day before to 2 days after surgery. Troponin T was measured on postoperative day 1, 3, 7, and before
discharge. Cardiac events included cardiac death or nonfatal Q-wave myocardial infarction at 30 days and
follow-up (mean 2.3 years).
Results Perioperative myocardial ischemia, troponin T release, 30-day events, and late cardiac events occurred in 29%,
23%, 4%, and 18%, respectively. In multivariate analysis, lower LDL cholesterol (per 10 mg/dl) correlated with
lower myocardial ischemia (odds ratio [OR] 0.87, 95% confidence interval [CI] 0.80 to 0.95), troponin T release
(OR 0.89, 95% CI 0.82 to 0.96), and 30-day (OR 0.89, 95% CI 0.78 to 1.00) and late cardiac events (hazard ra-
tio 0.91, 95% CI 0.84 to 0.96). Higher statin doses (per 10% of maximum recommended dose) correlated with
lower myocardial ischemia (OR 0.85, 95% CI 0.76 to 0.93), troponin T release (OR 0.84, 95% CI 0.76 to 0.93),
and 30-day (OR 0.62, 95% CI 0.40 to 0.96) and late cardiac events (hazard ratio 0.76, 95% CI 0.65 to 0.89),
even after adjusting for LDL cholesterol. Significantly higher perioperative heart rate variability was observed in
patients with higher statin doses.
Conclusions Higher statin doses and lower LDL cholesterol correlate with lower perioperative myocardial ischemia, periopera-
tive troponin T release, and 30-day and late cardiac events in major vascular surgery. (J Am Coll Cardiol 2007;
50:1649–56) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.046a
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ln the 30 million individuals undergoing noncardiac vascular
urgery in the U.S. annually, cardiac complications remain the
eading cause of perioperative morbidity and mortality. A
ooled analysis found an incidence of 6.2% (range 2.2% to
9.0%) for the composite end point of perioperative myocardial
nfarction or cardiac death in unselected patients 40 years of
rom the Departments of *Cardiology, †Vascular Surgery, and ‡Anesthesiology,
rasmus Medical Center, Rotterdam, the Netherlands; §Department of Cardiology,
arshfield Clinics, Marshfield, Wisconsin; and the ¶Department of Cardiology,
eiden University Medical Center, Leiden, the Netherlands. Davis Waters, MD,
ACC, acted as Guest Editor for this article.n
Manuscript received May 15, 2007; revised manuscript received June 20, 2007,
ccepted June 21, 2007.ge (1). Ischemic myocardial injury also remains a common
omplication that is observed in up to 41% of patients as
etected by continuous 12-lead electrocardiographic monitor-
ng and in up to 25% of patients as detected by elevated
roponin T levels (2). During recent years, 3-hydroxy-3-
ethyl-glutaryl-CoA reductase inhibitors (statins) have
merged as promising cardioprotective drugs in the primary
revention of cardiac events and mortality in patients under-
oing major vascular surgery (3–5).
Although studies have shown that lower cholesterol levels
re associated with improved outcome, optimal cholesterol
evels in patients scheduled for major vascular surgery are
ot well known (6). The main effect of statins is believed to
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Statins and Myocardial Ischemia October 23, 2007:1649–56be a reduction in cholesterol lev-
els that attenuates the atheroscle-
rotic process; however, statins
also may have effects beyond
their lipid-lowering properties
(7). Controversy exists regard-
ing whether statins have a pos-
itive effect on the cardiac au-
tonomous nervous system (8).
Because decreased heart rate vari-
ability may trigger ischemic events,
an improvement of heart rate
variability by statins may be a
potential mechanism of cardio-
protection (9).
The current prospective study
was conducted to clarify the fol-
lowing: 1) are higher statin doses
and lower cholesterol levels asso-
iated with reduced myocardial compromise on a subclinical
evel, i.e., myocardial ischemia assessed with continuous
2-lead electrocardiographic monitoring and troponin T
elease; 2) are higher statin doses and lower cholesterol
evels associated with improved clinical cardiac outcome; 3)
re statins cardioprotective independent of cholesterol lev-
ls; and 4) are statins associated with perioperative heart rate
ariability.
ethods
atients. The study population consisted of 359 patients
ndergoing elective abdominal aortic aneurysm repair (n 
75), peripheral artery bypass surgery (n 127), and carotid
rtery surgery (n  57) at the Erasmus Medical Center in
otterdam, the Netherlands, during the period of 2002 to
006. The study was approved by the hospital’s ethics
ommittee and performed with the informed consent of all
atients. Patients with a cardiac pacemaker, left ventricular
ypertrophy, left or right bundle branch block, or atrial
brillation were excluded. No patient presented with a
yocardial infarction within 6 months before surgery.
atients who participated in clinical intervention trials at or
utside of the Erasmus Medical Center (i.e., the DE-
REASE [Dutch Echocardiographic Cardiac Risk Evalu-
tion Applying Stress Echo]-II, -III, and -V trials) also
ere excluded. Patients were enrolled up to 3 months before
urgery at the outpatient clinic. At study enrollment, a
etailed cardiac history was obtained and patients were
creened for hypertension (blood pressure 140/90 mm
g), diabetes (fasting glucose 7.0 mmol/l, or insulin
herapy), renal failure (serum creatinine 2.0 mg/dl [177
mol/l]), smoking, and a history of cerebrovascular events.
n all patients, beta-blockers were considered before surgery
o obtain perioperative heart rates of 60 to 65 beats/min.
obutamine stress echocardiography. Before surgery, all
Abbreviations
and Acronyms
LDL  low-density
lipoprotein
MRTD  maximum
recommended therapeutic
dose
NN  normal-to-normal
rMSSD  square root of
the mean squared
differences of successive
normal-to-normal intervals
SDANN  standard
deviation of the average
normal-to-normal intervals
SDNN  standard deviation
of the normal-to-normal
intervalsatients underwent dobutamine stress echocardiography for bhe assessment of coronary artery disease. Dobutamine
tress echocardiography was performed according to estab-
ished protocols. The left ventricle was divided into 17
egments, and wall motion was scored on a 5-point scale
1 normal, 2 mild hypokinesis, 3 severe hypokinesis,
 akinesis, 5  dyskinesis). The results were considered
ositive if wall motion in any segment decreased by 1
rade during testing. Patients with positive dobutamine
tress echocardiography results were referred for further
ardiac management. It was not standard policy to perform
rophylactic preoperative coronary artery revascularization
n patients with stress-induced ischemia, with the exception
f patients in whom results were suggestive for left main
tenosis.
tatin dose and cholesterol measurements. Type, dose,
nd duration of statins were noted at enrollment in all statin
sers. The dose of statin therapy was converted to the
ercentage of maximum recommended therapeutic dose
MRTD) according to the U.S. Food and Drug Adminis-
ration’s Center for Drug Evaluation and Research database
10). The MRTD for simvastatin, pravastatin, and fluva-
tatin was 0.667 mg/kg/day. A MRTD of 0.333 mg/kg/day
as used for atorvastatin and rosuvastatin. The duration of
tatin therapy was calculated from time of prescription to
ime of surgery. Long-term statin therapy was defined as
tatin treatment 3 months before surgery. All patients
ho presented with hypercholesterolemia at enrollment
plasma low-density lipoprotein [LDL] cholesterol 200
g/dl) received statins. After 2003, LDL cholesterol levels
ere targeted to levels 100 mg/dl. During the study
eriod, high-risk surgery has not been a standard indication
or statin treatment. Patients continued statin treatment
fter hospital discharge. Cholesterol levels were measured at
nrollment and 1 day before surgery. For the current
nalysis, measurements obtained at the day before surgery
ere used. Measurements were obtained with an automated
nzymatic method and included LDL cholesterol, high-
ensity lipoprotein cholesterol, triglycerides, and total
holesterol.
ssessment of perioperative myocardial ischemia. Pa-
ients were continuously monitored with a 10-electrode,
2-lead digital electrocardiogram recorder (DR180 Dig-
tal Recorder, NorthEast Monitoring Inc., Maynard, Mas-
achusetts) starting 1 day before surgery up to 2 days after.
ecordings were performed in the continuous 12-lead mode
ith a recording length of 10 s/min. The frequency response
as 0.05 to 150 Hz. Electrocardiographic data were initially
rocessed by a technician and analyzed by 2 experienced
ardiologists who were blinded to the patient’s clinical data.
fter excluding all abnormal QRS complexes, the ambula-
ory electrocardiography recordings were analyzed for ST-
egment deviations. A continuous ST-segment trend was
enerated, and all potential ischemic episodes were identi-
ed. Episodes of ischemia were defined as reversible ST-
egment changes, lasting at least 1 min and shifting from
aseline to more than 0.1 mV (1 mm). The baseline ST-
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October 23, 2007:1649–56 Statins and Myocardial Ischemiaegment level was defined as the average ST-segment during a
table period (duration of 20 min) preceding each ischemic
pisode. The ST-segment change was measured 60 ms after
he J point. If the J point fell within the T-wave, the
T-segment change was measured 40 ms after that point.
ssessment of perioperative troponin T release. Tropo-
in T levels were measured on postoperative days 1, 3, and
, before discharge, and whenever clinically indicated by
lectrocardiogram changes, consistent with myocardial isch-
mia or infarction. Troponin T level was measured by an
lectrochemiluminescence immunoassay on the Elecsys
010 (Roche Diagnostics, Mannheim, Germany). The rec-
mmended lower limit of 0.03 ng/ml was used to define
ositive troponin T levels because lower levels do not meet
he imprecision criteria of 10%.
linical cardiac outcome. Study end points were major
ardiac events (cardiac death and nonfatal Q-wave myocar-
ial infarction) during the perioperative period (30-day
eriod after surgery) and during follow-up (mean 2.3 years).
uring follow-up, outpatient visits were scheduled every 3
onths after discharge. Cardiac death was defined as death
aused by acute myocardial infarction, cardiac arrhythmias,
ongestive heart failure, or sudden death. Nonfatal myocar-
ial infarction was diagnosed when at least the following
ere present: elevated cardiac enzyme levels, development
f new Q waves (1 mm or30 ms), and typical symptoms
f angina pectoris. No patients were lost to follow-up.
ssessment of perioperative heart rate variability. Heart
ate variability was computed for each subject using time-
omain analysis of short-term 5-min preoperative, intraop-
rative, and postoperative recordings. Consecutive 5-min
ecordings of 2-h periods were obtained in a standard
ashion at the evening before surgery, during the first 2 h of
urgery, and at the second evening after surgery. The
verage heart rate variability of the 5-min recordings during
he 2-h period was calculated. We used standard time
omain measures including the standard deviation of the
ormal-to-normal (NN) intervals (SDNN) and the square
oot of the mean squared differences of successive NN
ntervals (rMSSD). The standard deviation of the average
N intervals (SDANN) and the mean of the 5-min
tandard deviations (SDNN index) also were calculated for
he first 24-h recording. This 24-h recording started the
vening before surgery and included nighttime and the
urgical period.
tatistical analysis. Continuous data were compared using
he Student t test and categorical data were analyzed using
he chi-square test with Yates correction. Binary logistic
egression analysis was used to evaluate the association of
tatin dose and cholesterol levels on perioperative myocar-
ial ischemia, troponin T release, and 30-day clinical cardiac
utcome. Cox proportional hazard analysis was used to
ssess the association of statin dose and cholesterol levels
ith late cardiac events. Propensity analysis is a reliable tool
o correct for selection bias (11). A propensity score for
tatin therapy was calculated, which was constructed using (ultiple logistic regression analysis. In multivariate analysis,
djustments were made for age, gender, coronary artery
isease (according to medical history or stress test results),
istory of congestive heart failure, cerebrovascular disease,
iabetes, renal failure, hypertension, type of surgery, cardio-
ascular medication (beta-blockers, aspirin, angiotensin-
onverting enzyme inhibitors, and calcium-channel block-
rs) and propensity scores. Analysis of variance techniques
ere used to compare heart rate variability between groups
f patients with different statin doses. Tests for heterogeneity
ere used to reveal a differential effect of statins between
atients with or without perioperative myocardial ischemia
nd/or troponin T release. Odds and hazard ratios are given
ith 95% confidence intervals. For all tests, a p value 0.05
2-sided) was considered significant. All analysis was per-
ormed using SPSS 12.0 statistical software (SPSS Inc., Chi-
ago, Illinois).
esults
aseline characteristics. The mean age of the study pop-
lation was 67  10 years, and 79% were male. A total of
87 (52%) patients received statin therapy. The following
tatins were used: simvastatin in 54 patients, pravastatin in
2 patients, fluvastatin in 35 patients, atorvastatin in 49
atients, and rosuvastatin in 7 patients. Long-term statin
herapy was recorded in 150 patients (42%). Statins were
ewly prescribed in 37 patients (10%). The mean dose of
tatins was 41 32% of MRTD. Patients with statins more
requently had a history of cerebrovascular events, hyper-
ension, and hypercholesterolemia as compared with pa-
ients without statins (Table 1). Propensity analysis showed
hat patients were more likely to have statins if they had a
istory of cerebrovascular events (p  0.001) and hypercho-
esterolemia (p  0.001). Propensity scores ranged from
.11 to 0.94. No differences in coronary artery disease, renal
ailure, diabetes, smoking, and dobutamine stress test results
ere observed between the 2 groups.
tatin dose and cholesterol levels in relation to myocar-
ial ischemia. A total of 187 ischemic episodes in 103
atients (29%) were detected during continuous 72-h 12-
ead electrocardiography. The median duration of an isch-
mic episode was 72 min (interquartile range 49 to 235
in). The median ST-segment deviation was 1.4 mm
interquartile range 1.0 to 2.4 mm). The highest incidence
f myocardial ischemia was detected in patients undergoing
bdominal aortic repair (34%), followed by patients with
ower extremity bypass surgery (25%) and carotid surgery
19%) (p  0.003). Univariate (Figs. 1 and 2, Table 2) and
ultivariate analysis (Table 2) showed that higher statin
oses and lower LDL cholesterol levels were both signifi-
antly associated with a lower incidence of myocardial
schemia. Higher statin doses remained significantly asso-
iated with a lower incidence of perioperative myocardial
schemia, after adjusting for baseline cholesterol levels
Table 2).
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Statins and Myocardial Ischemia October 23, 2007:1649–56tatin dose and cholesterol levels in relation to troponin
release. Troponin T release was detected in 83 patients
23%). The median troponin T value was 0.5 ng/ml (inter-
uartile range 0.1 to 0.8 ng/ml). The highest incidence of
roponin T release was observed in patients undergoing
bdominal aortic repair (29%), followed by patients with
ower extremity bypass surgery (22%) and carotid surgery
9%) (p  0.001). Univariate (Fig. 1, Table 2) and multi-
ariate analysis (Table 2) showed that higher statin doses
nd lower LDL cholesterol levels were both significantly
Baseline Characteristics of the StudyPopu ation According to Statin Therapy (n  35
Table 1 Baseline Characteristics of the StuPopulation According to Statin The
Characteristic Statin
Age (yrs)
Male 1
Angina pectoris
History of myocardial infarction
Previous coronary revascularization
History of congestive heart failure
History of cerebrovascular event
Renal failure
Diabetes
Hypertension
Hypercholesterolemia 1
Current or past smoking 1
Aspirin 1
Angiotensin-converting enzyme inhibitors
Beta-blockers 1
Calcium channel blockers
Stress-induced myocardial ischemia
Low-density lipoprotein cholesterol (mg/dl) 1
High-density lipoprotein cholesterol (mg/dl)
Triglycerides (mg/dl) 1
Total cholesterol (mg/dl) 1
Values are expressed as mean ( SD) or n (%).
Figure 1 Incidence of Myocardial
Ischemia and Troponin T Release
The lowest incidence of myocardial ischemia and troponin T release in the peri-
operative period was observed in patients with statin doses of more than 50%
of the maximum recommended therapeutic dose.ssociated with a lower incidence of troponin T release.
igher statin doses remained significantly associated with a
ower incidence of troponin T release, irrespective of base-
ine cholesterol levels (Table 2).
tatin dose and cholesterol levels in relation to clinical
ardiac outcome. Perioperative cardiac death and nonfatal
-wave myocardial infarction occurred in 3% and 1% of
atients, respectively. Late cardiac death and nonfatal
-wave myocardial infarction occurred in 13% and 5% of
n  359)
187) No Statins (n  172) p Value
10 67 10 0.8
.4) 143 (83.1) 0.07
.7) 27 (15.7) 0.5
.4) 68 (39.5) 0.5
.6) 21 (12.2) 0.2
) 5 (2.9) 0.4
.2) 33 (19.2) 0.001
) 6 (3.5) 0.3
.0) 25 (14.5) 0.7
.5) 59 (34.4) 0.02
.2) 22 (12.8) 0.001
.4) 105 (61.0) 1.0
.5) 93 (54.1) 1.0
.8) 40 (23.3) 0.4
.3) 124 (72.7) 0.8
.1) 49 (28.5) 0.3
.3) 42 (24.4) 0.2
38 136 43 0.001
16 45 17 0.02
71 190 101 0.001
42 212 51 0.001
Figure 2 Incidence of Myocardial
Ischemia and Troponin T Release
The incidence of myocardial ischemia and troponin T release in the periopera-
tive period was lowest in patients with baseline low-density lipoprotein (LDL)
cholesterol levels below 80 mg/dl.9)
dy
rapy (
s (n 
66
41 (75
35 (18
68 (36
33 (17
9 (4.8
64 (34
11 (5.9
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October 23, 2007:1649–56 Statins and Myocardial Ischemiaatients, respectively. During follow-up, statins were
iscontinued in 2 patients (1%) because of side effects
myopathy in 1 patient and nausea and/or diarrhea in
nother). In multivariate analysis, higher statin doses and
ower LDL cholesterol levels were both significantly
ssociated with a lower incidence of 30-day and late
ardiac events (Table 3). Higher statin doses remained
ignificantly associated with lower 30-day and late cardiac
vents, after adjusting for absolute baseline cholesterol
evels. In subgroup analysis, the long-term benefit of
tatin therapy was also comparable between patients with
nd without myocardial ischemia and/or troponin T
elease (p for interaction 0.92).
tatin Therapy in Relation to Perioperative Ischemia androponin T Release in Patients Undergo ng Major V scular Surgery
Table 2 Statin Therapy in Relation to Perioperative Ischemia aTroponin T Release in Patients Undergoing Major Vasc
Perioper
Characteristic Univariate
Statins
Statin therapy (n  187) 0.29 (0.17–0.
Statin treatment 3 months† (n  37) 0.22 (0.08–0.
Statin treatment 3 months† (n  150) 0.31 (0.18–0.
Statin dose per 10% increase of MRTD 0.82 (0.75–0.
Statin dose per 10% increase of MRTD (with adjustment
for baseline LDL cholesterol)
0.87 (0.80–0.
Level of baseline cholesterol*
LDL cholesterol (per 10-mg/dl decrease) 0.89 (0.83–0.
HDL cholesterol (per 10-mg/dl decrease) 1.07 (0.91–1.
Triglycerides (per 10-mg/dl decrease) 0.96 (0.93–0.
Total cholesterol (per 10-mg/dl decrease) 0.87 (0.83–0.
Adjusted for age, gender, coronary artery disease (according to medical history or stress test resul
f surgery and cardiovascular medication (beta-blockers, aspirin, angiotensin-converting enzyme inh
reatment.
CI  confidence interval; HDL  high-density lipoprotein; LDL  low-density lipoprotein; MRTD
tatin Therapy in Relation to Perioperative and Late Cardiac Outco
Table 3 Statin Therapy in Relation to Perioperative and Late C
Perioperati
Q-Wave My
Characteristic Univariate
Statins
Statin therapy (n  187) 0.31 (0.10–0.
Statin treatment 3 months† (n  37) ‡
Statin treatment 3 months† (n  150) 0.24 (0.05–0.
Statin dose per 10% increase of MRTD 0.60 (0.39–0.
Statin dose per 10% increase of MRTD (with adjustment
for baseline LDL cholesterol)
0.60 (0.37–0.
Level of baseline cholesterol*
LDL cholesterol (per 10-mg/dl decrease) 0.86 (0.76–0.
HDL cholesterol (per 10-mg/dl decrease) 1.05 (0.69–1.
Triglycerides (per 10-mg/dl decrease) 1.01 (0.93–1.
Total cholesterol (per 10-mg/dl decrease) 0.98 (0.87–1.
Adjusted for age, gender, coronary artery disease (according to medical history or stress test resul
f surgery and cardiovascular medication (beta-blockers, aspirin, angiotensin-converting enzyme inh
reatment. ‡No perioperative major cardiac events occurred in patients with statin treatment 3 months
HR  hazard ratio; other abbreviations as in Table 2.tatins and heart rate variability. Heart rate variability
as highest before and lowest during surgery (SDNN 47 
8 ms, 34  23 ms, and 39  29 ms before, during, and
fter surgery, respectively [p  0.007]). We found that
ower heart rate variability before surgery (SDNN per 10 ms
ecrease) significantly predicted myocardial ischemia during
r after surgery (OR 1.59, 95% CI 1.19 to 2.13) and
roponin T release after surgery (OR 1.54, 95% CI 1.17
o 2.01). Lower heart rate variability during surgery
SDNN per 10-ms decrease) also significantly predicted
yocardial ischemia after surgery (OR 1.71, 95% CI 1.14
o 2.57) and troponin T release after surgery (OR 1.55,
5% CI 1.13 to 2.11). Higher statin doses correlated
urgery
yocardial Ischemia
 103)
(95% CI)
Perioperative Troponin T Release
(n  83)
OR (95% CI)
Multivariate* Univariate Multivariate*
0.33 (0.18–0.60) 0.33 (0.19–0.55) 0.24 (0.12–0.47)
0.52 (0.13–2.03) 0.25 (0.08–0.72) 0.75 (0.19–2.96)
0.30 (0.17–0.53) 0.35 (0.18–0.62) 0.32 (0.17–0.59)
0.85 (0.76–0.93) 0.85 (0.77–0.94) 0.84 (0.76–0.93)
0.88 (0.80–0.96) 0.90 (0.81–0.98) 0.87 (0.79–0.95)
0.87 (0.80–0.95) 0.93 (0.87–1.00) 0.89 (0.82–0.96)
1.06 (0.88–1.28) 1.14 (0.95–1.37) 1.19 (0.96–1.47)
0.96 (0.93–0.98) 0.96 (0.93–0.98) 0.95 (0.93–0.98)
0.86 (0.81–0.91) 0.93 (0.87–0.98) 0.91 (0.85–0.96)
ory of congestive heart failure, cerebrovascular disease, diabetes, renal failure, hypertension, type
and calcium-channel blockers), and propensity scores. †In comparison with patients with no statin
mum recommended therapeutic dose; OR  odds ratio.
Patients Undergoing Major Vascular Surgery
c Outcome in Patients Undergoing Major Vascular Surgery
diac Death or Nonfatal
ial Infarction (n  15)
(95% CI)
Late Cardiac Death or Nonfatal Q-Wave
Myocardial Infarction (n  64)
HR (95% CI)
Multivariate* Univariate Multivariate*
0.32 (0.10–0.96) 0.42 (0.23–0.77) 0.41 (0.21–0.75)
‡ 0.75 (0.02–3.22) 0.81 (0.05–4.15)
0.25 (0.06–0.97) 0.50 (0.28–0.90) 0.52 (0.29–0.93)
0.62 (0.40–0.96) 0.75 (0.64–0.89) 0.76 (0.65–0.89)
0.66 (0.42–0.98) 0.78 (0.65–0.96) 0.80 (0.67–0.94)
0.89 (0.78–1.00) 0.93 (0.86–0.99) 0.91 (0.84–0.96)
1.10 (0.72–1.70) 0.92 (0.78–1.09) 1.05 (0.87–1.24)
1.01 (0.93–1.08) 0.99 (0.97–1.02) 1.01 (0.97–1.03)
0.95 (0.85–1.07) 0.94 (0.90–1.01) 0.94 (0.88–1.00)
ory of congestive heart failure, cerebrovascular disease, diabetes, renal failure, hypertension, type
and calcium-channel blockers), and propensity scores. †In comparison with patients with no statinnd
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Statins and Myocardial Ischemia October 23, 2007:1649–56ignificantly with higher SDNN before, during, and after
urgery (Table 4).
iscussion
his study found that higher statin doses and lower LDL
holesterol levels were both significantly associated with a
ower incidence of perioperative myocardial ischemia, peri-
perative troponin T release, and 30-day and late cardiac
vents in patients undergoing major vascular surgery.
igher statin doses remained significantly associated with
mproved cardiac outcome, irrespective of baseline choles-
erol levels. Higher statin doses also correlated significantly
ith higher perioperative heart rate variability. These results
uggest that statins are cardioprotective on a clinical and
ubclinical level and that they should be considered in all
atients undergoing major vascular surgery.
tatins and myocardial ischemia. The association be-
ween statin treatment and temporary or prolonged myo-
ardial ischemia is not well known. Myocardial ischemia in
he perioperative setting may arise either from increased
yocardial oxygen demand or reduced supply. Factors that
ncrease myocardial oxygen demand are mainly tachycardia
nd hypertension resulting from surgical stress, postopera-
ive pain, interruption of beta-blocker use, or the use of
ympathomimetic drugs. In contrast, decreased supply may
e the result of hypotension, vasospasm, anemia, hypoxia, or
oronary artery plaque rupture. Experimental animal studies
ave shown that administration of statins before induction
f myocardial ischemia improved myocardial viability, re-
uced the extent of inflammatory cell accumulation in the
schemic myocardium, and preserved coronary blood flow,
Association Between Heart Rate Variability and
Table 4 Association Between Heart Rate Va
Characteristic
Statins >50% of MRTD
(n  53)
Before surgery
SDNN (ms) 52 29
rMSSD (ms) 40 35
Heart rate (beats/min) 68 11
During surgery
SDNN (ms) 39 27
rMSSD (ms) 32 31
Heart rate (beats/min) 73 13
After surgery
SDNN (ms) 48 45
rMSSD (ms) 34 32
Heart rate (beats/min) 76 13
First 24-h recording
SDNN (ms) 139 44
SDANN (ms) 116 39
SDNN index (ms) 47 28
rMSSD (ms) 53 47
Heart rate (beats/min) 72 12
MRTD  maximum recommended therapeutic dose; rMSSD  squ
intervals; SDANN  standard deviation of the average normal-to-normhich was attributed to a reduction in adhesion molecule bxpression of the endothelial monolayer and to an increase
n the bioavailability of nitric oxide (12). The results of the
urrent study support the view that myocardial ischemia is
imited not only by cholesterol-lowering properties of statin
herapy, but also by potential mechanisms such as endothe-
ial function improvement and increase in nitric oxide with
reservation of coronary blood flow (13).
tatins and clinical cardiac outcome. Large trials have
onsistently shown that statins reduce cardiovascular morbidity
nd mortality in high-risk patients (14–17). Marked reduc-
ions in perioperative cardiovascular events have also been
hown in patients undergoing major vascular surgery (3–5).
he reduction of acute thrombotic events may be explained by
therosclerotic plaque attenuation and stabilization. Intensive
tatin therapy can result in significant regression of atheroscle-
osis, as shown in the ASTEROID (A Study to Evaluate the
ffect of Rosuvastatin on Intravascular Ultrasound-Derived
oronary Atheroma Burden) trial (18). In human carotid
laques, statins have been shown to decrease lipids, lipid
xidation, inflammation, matrix metalloproteinase-2, and cell
eath and to increase tissue inhibitor of metalloproteinase 1
nd collagen (7). According to the current results, every
0-mg/dl reduction in baseline LDL cholesterol was signifi-
antly associated with a 13% lower risk of perioperative cardiac
vents. Moreover, a sustained beneficial effect of high-dose
tatins and low LDL cholesterol levels was observed for late
ardiac events.
tatins and heart rate variability. Reduced heart rate
ariability during surgery is most probably the result of
nesthetic agents and can be a sign of increased sympathetic
r reduced vagal activity. Reduced heart rate variability has
in Therapy
lity and Statin Therapy
tins 1% to 50% of MRTD
(n  134)
No Statins
(n  172) p Value
48 28 37 19 0.001
36 31 28 22 0.01
67 12 68 12 0.7
32 21 29 19 0.002
26 19 25 23 0.06
71 14 72 13 0.4
39 24 36 31 0.04
33 30 29 28 0.1
77 14 77 14 0.8
131 45 119 42 0.001
114 39 88 30 0.001
40 18 38 17 0.002
49 29 50 37 0.3
72 13 72 13 0.9
t of the mean squared differences of successive normal-to-normal
rvals; SDNN  standard deviation of the normal-to-normal intervals.Stat
riabi
Staeen associated with sudden arrhythmic cardiovascular and
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October 23, 2007:1649–56 Statins and Myocardial Ischemiaoncardiovascular mortality in many studies. A recent study
howed that a temporal decrease in heart rate variability, i.e.,
agal withdrawal, can act as a precipitating factor for
yocardial ischemia (9). High-frequency components of
eart rate variability showed a consistent decrease before an
schemic event and before the electrocardiographic appear-
nce suggestive of coronary spasm (9). We also observed
hat lower heart rate variability in the period preceding
yocardial ischemia and troponin T release significantly
redicted its occurrence in the period after this measure-
ent. The beneficial effect of statins on autonomic function
as been suggested in previously published studies
8,19,20). Our results showed that higher statin doses were
ignificantly associated with higher SDNN. Heart rate, a
eterminant of heart rate variability, was similar between
atients with different statin doses. These observations led
s to the hypothesis that in situations of decreased heart rate
ariability and increased myocardial oxygen demand, statins
ay exert an anti-ischemic effect by modulating the auto-
omic nervous system.
linical implications. An important observation in this
tudy was that statins were only prescribed in 52% of
atients. This reflects the need for evidence supporting the
enefit of statin treatment in patients undergoing major
ascular surgery and the need for awareness among physi-
ians. Statins have not yet been recommended as perioper-
tive medical treatment by the American College of
ardiology/American Heart Association (21). Coronary
therosclerosis is highly prevalent among patients undergo-
ng major vascular surgery, with angiographic coronary
bnormalities observed in up to 92% of patients (22).
urgery places the patient at additional increased risk of
erioperative events (23). Therefore, the recommendations
o achieve LDL cholesterol levels 100 mg/dl in people
ith (risk equivalents of) coronary artery disease according
o the guidelines of the National Cholesterol Education
rogram Adult Treatment Panel III and the European
uidelines on cardiovascular disease prevention in clinical
ractice should be extrapolated to patients undergoing
ajor vascular surgery (24,25). The current study further
rovides evidence that additional risk reduction can be
chieved by achieving LDL cholesterol levels 80 mg/dl.
tudy limitations. Several limitations should be addressed.
n this observational study, statins were not assigned ran-
omly; however, the 2 groups were comparable in demo-
raphics and cardioprotective drugs. In addition, multivar-
ate analysis and propensity scores were used to adjust for
ossible confounding factors. Second, the results apply to
atients undergoing major noncardiac vascular surgery, and
ur findings may not be generalized to patients undergoing
eneral or low-risk surgery. Third, a lower cutoff level of
.03 ng/ml was used to define positive troponin T levels.
ower troponin T levels were not used because they do not
eet the imprecision criteria (coefficient of variation) of
10%. Finally, carotid artery surgery has been associated
ith heart rate change secondary to baroreceptor reflexes.he inclusion of these patients may potentially have con-
ounded the heart rate variability results.
onclusions
igher statin doses and lower LDL cholesterol levels were
oth significantly associated with a lower incidence of
erioperative myocardial ischemia during continuous 12-
ead electrocardiographic monitoring, perioperative tropo-
in T release, and 30-day and late cardiac events. Analysis
f the 72-h 12-lead electrocardiographic recordings further
howed that perioperative heart rate variability was signifi-
antly higher in patients with higher statin doses. These
esults suggest that statins are cardioprotective on a clinical
nd subclinical level.
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